Table 2 Baseline characteristics of study participants

Age, years

70.43 ± 9

Female sex—no. (%)

34 (48.6%)

Race—no. (%)

 Hispanic

41 (58.6%)

 African American

22 (31.4%)

 Asian Pacific Islander

4 (5.7%)

 White

3 (4.3%)

Lower extremity arterial disease

 Above the knee—no. (%)

38 (54.3%)

 Below the knee—no. (%)

32 (45.7%)

Cardiovascular risk factors

 Diabetes mellitus, type 2 no. (%)

70 (100.0%)

 Hypertension no. (%)

64 (91.4%)

 Hyperlipidemia no. (%)

69 (98.6%)

 Smoking, current or past use no. (%)

34 (48.6%)

 Chronic kidney disease no. (%)

10 (14.3%)

 HIV infection no (%)

22 (31.4%)

 Statin use no. (%)

65 (92.9%)

 High-intensity no. (%)

30 (42.9%)

 Moderate-intensity no. (%)

33 (47.1%)

 Low-intensity no. (%)

2 (2.9%)

 Beta-blockers no. (%)

43 (61.4%)

 ACE inhibitor or ARB no. (%)

52 (74.3%)

Anti-diabetic medications

 Insulin no. (%)

28 (40.0%)

 Metformin no. (%)

37 (52.9%)

 Sulfonylurea no. (%)

14 (20.0%)

 DP4 no. (%)

24 (34.3%)

 GLP agonist no. (%)

6 (8.6%)

 Glitazone no. (%)

4 (5.7%)

 SGLT2 no. (%)

2 (2.9%)